(Total Views: 596)
Posted On: 10/22/2020 4:13:16 PM
Post# of 154138
Index,
Itolizumab given EUA based on open label trial, not much better than EIND with a cohort analysis.
As has been EXHAUSTIVELY discussed, the NEWS2 secondary endpoint is vastly more indicative of effect than the primary endpoint. The FDA just does not casre about therapeutics for mild cases.
Itolizumab given EUA based on open label trial, not much better than EIND with a cohort analysis.
As has been EXHAUSTIVELY discussed, the NEWS2 secondary endpoint is vastly more indicative of effect than the primary endpoint. The FDA just does not casre about therapeutics for mild cases.
(4)
(1)
